1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Patient demographics
All Patients WHO II WHO III WHO IV
No. of patients 
    Total 90 24 26 40
    Presurgery 43 (47.8%) 15 (62.5%) 15 (57.7%) 13 (32.5%)
    Postsurgery, pretreatment 15 (16.7%) 5 (20.8%) 3 (12.0%) 7 (17.5%)
    On treatment (radiation, chemotherapy, and so forth) 32 (35.6%) 4 (16.7%) 8 (32.0%) (2 on bevacizumab) 20 (50.0%) (2 on bevacizumab)
Age (yr) 
    Mean 50.3 44 46.3 56.8
    Range 15 (pediatric)–90 22–90 15 (pediatric)–70 19–81
Sex 
    Male 59 (65.6%) 10 (41.7%) 17 (65.4%) 32 (80.0%)
    Female 31 (35.4%) 14 (58.3%) 9 (34.6%) 8 (20.0%)
IDH status 
    Wild-type 51 (56.7%) 2 (8.3%) 11 (42.3%) 38 (95.0%)
    Mutant 39 (43.3%) 22 (91.7%) 15 (57.7%) 2 (5.0%)
MGMT-promoter methylation status 
    Unmethylated 27 (30.0%) 1 (4.2%) 6 (23.1%) 20 (50.0%)
    Methylated 17 (18.9%) 4 (16.7%) 1 (3.8%) 12 (30.0%)
    NA 46 (51.1%) 19 (79.2%) 19 (73.1%) 8 (20.0%)
Histology 
    Astrocytoma 25 (27.8%) 10 (41.7%) 15 (57.7%) NA
    Oligoastrocytoma 11 (12.2%) 2 (8.3%) 9 (34.6%) NA
    Oligodendroglioma 14 (15.6%) 12 (50.0%) 2 (7.7%) NA
Note:—NA indicates not applicable.
a Data are number and percentage unless otherwise indicated.